PA
OCUL icon

Parallel Advisors’s Ocular Therapeutix OCUL Stock Holding History

Parallel Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$805 Buy
+82
New +$743 ﹤0.01% 3724
2025
Q1 		– Sell
-1
Closed -$9 – 3621
2024
Q4 		$9 Hold
1
– – ﹤0.01% 3505
2024
Q3 		$9 Buy
+1
New +$8 ﹤0.01% 3382
2022
Q1 		– Sell
-1,012
Closed -$7K – 3174
2021
Q4 		$7K Buy
+1,012
New +$7.86K ﹤0.01% 2268

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parallel Advisors's OCUL Position: Q2 2026 in Review

Parallel Advisors opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 82 shares worth $805. The stake represents ﹤0.01% of the portfolio and ranks #3724 among its holdings. This is a return to the name: Parallel Advisors previously reported a position in OCUL as recently as Q4 2024.

Parallel Advisors first reported a position in OCUL in Q4 2021 and has held it in 4 quarters since. The position peaked at $7K in Q4 2021. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Parallel Advisors held 82 shares of Ocular Therapeutix worth $805 as of Q2 2026.
  • Ocular Therapeutix was a new Parallel Advisors position in Q2 2026.
  • Ocular Therapeutix made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3724 holding.
  • Parallel Advisors first reported a position in Ocular Therapeutix in Q4 2021 and has held it in 4 quarters since.
  • Parallel Advisors's Ocular Therapeutix position peaked at $7K in Q4 2021.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.